Pharmacokinetic and Early Efficacy of OPT101 in Patients With Type 1 Diabetes Mellitus

PHASE2Active, not recruitingINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

May 27, 2025

Primary Completion Date

May 19, 2026

Study Completion Date

August 19, 2028

Conditions

Type I Diabetes

Interventions

DRUG

OPT101

Subcutaneous injection.

OTHER

OPT101 Placebo to Match (PTM)

5% Dextrose (w/v)

Trial Locations (1)

Rainier Clinical Research Center, Renton

All Listed Sponsors

lead

Op-T LLC

INDUSTRY

NCT06964087 - Pharmacokinetic and Early Efficacy of OPT101 in Patients With Type 1 Diabetes Mellitus | Biotech Hunter | Biotech Hunter